Compare RPGL & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPGL | IMMP |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | Singapore | Australia |
| Employees | 8 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.0M | 76.6M |
| IPO Year | N/A | 2012 |
| Metric | RPGL | IMMP |
|---|---|---|
| Price | $2.41 | $0.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | ★ 4.5M | 904.8K |
| Earning Date | 05-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.29 |
| 52 Week High | $13.06 | $3.53 |
| Indicator | RPGL | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 34.00 |
| Support Level | $0.31 | $0.29 |
| Resistance Level | $8.44 | $0.39 |
| Average True Range (ATR) | 1.62 | 0.03 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 16.97 | 6.97 |
Republic Power Group Ltd is a provider of customized ERP software solutions, consulting and technical support services, and peripheral hardware to corporate clients and government agencies, including airports, cruise terminals, and technology, trading, and logistics companies. The Company operates from Singapore and has historically served clients in Singapore and Malaysia, offering ERP systems with functions such as accounting, procurement, workflow automation, real-time monitoring, and capabilities including planning, surveillance, and threat detection. The Company leverages artificial intelligence and modular algorithms to address complex operational requirements and integrates sensors, controls, and other hardware to enable IoT connectivity with autonomous or semiautonomous outcomes.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.